BOUCHERVILLE, QC, Dec. 23, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or " LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has completed the closing of an initial tranche of its previously announced brokered private placement offering (the "Brokered Offering") of unsecured convertible debentures (the "Debentures") for total gross proceeds of $10,000,000 (the "Offering"). The Brokered Offering was led by Bloom Burton Securities Inc. (the "Lead Agent") on behalf of a syndicate including Research Capital Corporation and Leede Financial Inc. (collectively with the Lead Agent, the "Agents"). The Debentures were issued at a price of $1,000 per Debenture, for $10,000,000 in gross proceeds. The Debentures bear interest at 10.0% per annum, payable semi-annually in arrears, and mature on December 31, 2029 at which time the aggregate principal amount of the Debentures is repayable in cash. The principal amount of each Debenture is convertible into common shares of the Corporation (the "Common Shares") at a conversion price of $0.45 per Common Share.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
